Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT

2026-526179-49-00 · tracked via the Priya Life Science EU tracker

Sponsor

Medical Center - University Of Freiburg

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Musculoskeletal Diseases

Decision date

03/08/2026

Enrollment target

166

Sites

Germany

Condition studied

Full-thickness cartilage defects of the knee

Investigational medicinal product(s)

MACI 500000 to 1000000 cells/cm2 implantation matrixSpherox 10-70 spheroids/cm2 implantation suspension

Eligibility

Age group

18-64 years

Sex

Female, Male

Primary endpoint

The primary efficacy endpoint is the KOOS5 (composite Knee injury and Osteoarthritis Outcome Score) at 24 months after randomisation

Endpoint detail

Following scores and questionnaires at 3, 6, 12, 24 months after randomisation: IKDC, KOOS5, KOOS subscales (Pain, Symptoms, ADL, Sport and Recreation, QOL), Lysholm, QOL SF-12, absence from work and incidence and number of revision surgeries.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526179-49-00 on CTIS ↗ ← All trials in the EU